Blue Shield of California enters accountable care agreement

Editorial Staff | | Health Exec | Policy & Regulations
California - 11.88 Kb
Blue Shield of California will enter a partnership with Dominican Hospital and Physicians Medical Group of Santa Cruz County on a three-year accountable care initiative.

The initiative is seeking to provide care to approximately 8,000 Blue Shield health maintenance organization members, including 5,200 members of the California Public Employees’ Retirement System.  

The partnership with the two Santa Cruz, Calif.-based healthcare organizations represent Blue Shield’s eighth venture into commercial accountable care organizations. Affected members are expected to see no increase in insurance costs over the first year of the collaboration and a small increase in the subsequent two years, according to the payer.

Editorial Staff

Related Content

Q&A: Proposed changes to Social Security Act would recognize pharmacists as healthcare providers
10 signs AI is ‘eating the world (of venture capital)’
Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.